DBV Technologies reported $-41110000 in Operating Profit for its fiscal quarter ending in June of 2025.




Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amarin USD -16755000 35.77M Mar/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
DBV Technologies USD -41110000 14.49M Jun/2025
Halozyme Therapeutics USD 202.44M 60.91M Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
United Therapeutics USD 276.9M 105.9M Jun/2025